One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...

A novel HIV vaccine candidate induces neutralising antibodies after a single dose in primates, potentially accelerating HIV prevention.

By Deena Beasley Feb 10 (Reuters) - Gilead Sciences on Tuesday issued a 2026 financial forecast that was at the low end of ...

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

South Africa has begun the first human trials of a locally developed HIV vaccine to defeat a virus that still kills around one person per minute worldwide.

The BRILLIANT 011 trial is testing two next-generation HIV vaccine components—BG505 GT1.1 and 426c.Mod.Core-C4b—administered ...

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...

According to the Washington Post (WP) and others on the 4th, local time, Fiji—with a population of less than 1 million—has ...

One in nine people in prisons globally have a history of injecting drug use and their risk of HIV, viral hepatitis and tuberculosis is up to 45 times higher than in the general population. Yet access ...

Researchers developed a DNA-scaffolded vaccine that achieves the first step in generating a significant population of B cells that produce broadly neutralizing antibodies against HIV.

South Africa has taken a pioneering step towards HIV vaccine development with the launch of the historic BRILLIANT 011 trial ...